These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Open innovation: share or die.. Talaga P Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629 [No Abstract] [Full Text] [Related]
4. The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Vallance P; Williams P; Dollery C Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455 [No Abstract] [Full Text] [Related]
5. What should be done to improve the productivity of neurological research? Moses H; Martin JB Ann Neurol; 2006 Dec; 60(6):647-51. PubMed ID: 17192925 [No Abstract] [Full Text] [Related]
6. [Open innovation for Japanese pharmaceutical companies]. Hoshino T Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):184-9. PubMed ID: 24107523 [No Abstract] [Full Text] [Related]
7. Algeta and Ablynx collaborate to discover and develop targeted cancer therapies. King G Future Med Chem; 2013 Feb; 5(2):123. PubMed ID: 23476969 [No Abstract] [Full Text] [Related]
8. Overcoming the obstacles in the pharma/biotech industry: 2008 update. Graul AI; Revel L; Rosa E; Cruces E Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298 [TBL] [Abstract][Full Text] [Related]
9. Industry support for medical centers grows. Dove A Nat Med; 2000 Sep; 6(9):948. PubMed ID: 10973295 [No Abstract] [Full Text] [Related]
10. Academic centers get turnaround advice. Japsen B Mod Healthc; 1995 Sep; 25(37):50, 52. PubMed ID: 10151382 [No Abstract] [Full Text] [Related]
12. Strategic R&D transactions in personalized drug development. Makino T; Lim Y; Kodama K Drug Discov Today; 2018 Jul; 23(7):1334-1339. PubMed ID: 29574213 [TBL] [Abstract][Full Text] [Related]
13. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development. Perakslis ED; Van Dam J; Szalma S Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001 [No Abstract] [Full Text] [Related]
14. Outlook: finding improved medicines: the role of academic-industrial collaboration. Chin-Dusting J; Mizrahi J; Jennings G; Fitzgerald D Nat Rev Drug Discov; 2005 Nov; 4(11):891-7. PubMed ID: 16247439 [TBL] [Abstract][Full Text] [Related]
15. Sun sets on protein initiative, casting shadow over drug discovery. Devitt E Nat Med; 2013 Nov; 19(11):1352. PubMed ID: 24202371 [No Abstract] [Full Text] [Related]
16. Market watch: Biopharma deal-making in 2014: a record year for M&A value. Micklus A; Muntner S Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786 [No Abstract] [Full Text] [Related]
17. The future of discovery chemistry: quo vadis? Academic to industrial--the maturation of medicinal chemistry to chemical biology. Hoffmann T; Bishop C Drug Discov Today; 2010 Apr; 15(7-8):260-4. PubMed ID: 20149893 [TBL] [Abstract][Full Text] [Related]
18. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. Woosley RL; Myers RT; Goodsaid F Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457 [TBL] [Abstract][Full Text] [Related]
19. Toward a virtuous cycle: the changing face of academic health centers. Wartman SA Acad Med; 2008 Sep; 83(9):797-9. PubMed ID: 18728428 [No Abstract] [Full Text] [Related]
20. [Open innovation and licensing in the pharmaceutical industry]. Yamasaki M Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):28-31. PubMed ID: 23842225 [No Abstract] [Full Text] [Related] [Next] [New Search]